Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality evaluation of randomized controlled trials of antipsychotic drugs for schizophrenia published in Chinese journals.

Schizophrenia research·2026
Same author

Improving research quality of psychological interventions in evidence-based medicine.

The lancet. Psychiatry·2026
Same author

Synthesis of pyrazolo[5,1-<i>a</i>]isoindoles <i>via</i> silver-mediated cascade cyclization of 1,5-enynes with diazo compounds.

Chemical communications (Cambridge, England)·2026
Same author

Regional homogeneity and interhemispheric connectivity alterations in major depressive disorder.

Asian journal of psychiatry·2026
Same author

Glutathione depletion activates cGAS-STING signaling via oxidative stress in preeclampsia.

Molecular immunology·2026
Same author

The effects of rTMS over orbitofrontal cortex on cognitive functions in first-episode schizophrenia.

Psychological medicine·2026
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Risperidone dose for schizophrenia.

Chunbo Li1, Jun Xia, Jijun Wang

  • 1Department of Biological Psychiatry, Shanghai Mental Health Center, Shanghai Jiaotong University, 600 Wan Ping Nan Road, Shanghai, China, 200030.

The Cochrane Database of Systematic Reviews
|October 13, 2009
PubMed
Summary
This summary is machine-generated.

Finding the optimal dose of risperidone for schizophrenia is crucial for balancing efficacy and side effects. Mid-range doses, specifically 4-6 mg/day, appear most effective, while ultra-low and high doses show limited benefits and increased adverse events.

Related Experiment Videos

Last Updated: Jun 19, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Area of Science:

  • Psychiatry and Pharmacology
  • Evidence-Based Medicine
  • Clinical Trial Analysis

Background:

  • Risperidone is a key antipsychotic for schizophrenia management.
  • Optimizing risperidone dosage is essential to maximize therapeutic benefits while minimizing adverse outcomes.
  • This review focuses on determining the optimal risperidone dose for schizophrenia treatment.

Purpose of the Study:

  • To establish dose-response relationships for risperidone in schizophrenia and related psychoses.
  • To identify the optimal risperidone dosage balancing efficacy and tolerability.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) from the Cochrane Schizophrenia Group Trials Register (July 2008).
  • Independent data extraction and analysis by two reviewers, with third-party arbitration for disagreements.
  • Calculation of relative risk (RR) and weighted mean differences (MD) for dichotomous and continuous data, respectively.

Main Results:

  • Ultra-low doses (<2 mg/day) were associated with significantly higher rates of early discontinuation due to insufficient response compared to standard-low doses (4-6 mg/day).
  • Low doses (2-4 mg/day) also showed increased early discontinuation compared to higher dose ranges (≥6 mg/day).
  • The 4-6 mg/day dose range demonstrated favorable outcomes regarding clinical response and adverse effects, particularly movement disorders, compared to higher doses (≥10 mg/day). High doses (≥10 mg/day) did not offer advantages and increased adverse events.

Conclusions:

  • A definitive optimal dose remains elusive due to trial quality limitations, suggesting potential overestimation of effects for mid-range doses.
  • The 4-6 mg/day dose range appears optimal for clinical response and tolerability.
  • Low doses (2-4 mg/day) may benefit first-episode patients, while high doses (≥10 mg/day) are not recommended due to increased adverse effects. Ultra-low doses (<2 mg/day) showed minimal efficacy.